Brittany Lovely | Authors


Disease Recurrence Not Significantly Delayed With Panvac Plus BCG in Advanced NMIBC

September 13, 2021

n a phase 2 study of patients with BCG-unresponsive non–muscle invasive bladder cancer, treatment with recombinant pox-viral vector vaccine Panvac plus bacillus Calmette-Guérin did not significantly improve clinical outcomes.

Elevated Antibody Titers May Be a Prognostic Marker in BCG-Unresponsive NMIBC

September 10, 2021

According to secondary analysis results of a phase 3 study, antibody titers and fold changes are possibly predictive of nadofaragene firadenovec efficacy in patients with bacillus Calmette-Guérun unresponsive non-muscle invasive bladder cancer.

Trastuzumab Deruxtecan Sustains Efficacy Benefit in HER2-Positive mCRC

June 08, 2021

With addition 16-month follow-up, the benefit of fam-trastuzumab deruxtecan-nxki as treatment of patients with HER2-overexpressing metastatic colorectal cancer showed results that were consistent with the primary analysis of the DESTINY-CRC01 trial study.